Spotlight Biotechnology/Microtechnology The Future of Biomarker Detection
Randox Laboratories has been supplying the world’s leading Contract Research Organisations (CRO), Pharmaceutical and Biotech companies for over 27 years with the ‘tools’ required to develop high quality pharmaceuticals faster, safer and more economically.
Following decades of scientific innovation and discovery, today it is inconceivable that any new drug would be developed without simultaneously looking at a multitude of biomarkers. It is widely accepted that the clinical application of validated biomarkers will revolutionise medicine over the coming years. Already pharmaceuticals are being sold with Pharmacogenomic labeling information related to optimising patient selection and personal dosage, but their role in diagnostics will be even more important.
With this in mind a key focus for Randox is to take any newly discovered biomarkers from the realm of research through to clinical utility, whether in the pharmaceutical industry and clinical trials or the wider healthcare industry. However, the process to successfully validate a biomarker is often just as lengthy and costly as for a drug candidate and key to this process is to provide accurate clinical trial results.
ADVERTORIAL
Randox’s Biochip Array Technology has been specifically developed to accelerate this validation process. This award-winning technology offers not only ‘diagnostic grade’ results which can be trusted, but the in-built accuracy, precision and specificity of this platform will greatly assist in study publications, clinical trial results and ultimately biomarker validation.
Circle no. 151
World's First Reusable Biochip Architecture
Fluidigm Corporation has announced it has developed the world's first reusable bio-chip architecture for the commercial market. These reusable integrated fluidic circuits (IFCs) will dramatically lower SNP genotyping costs and are designed to support accelerated sample throughput, while maintaining data quality of 99.75% or greater accuracy and 99% or greater call rates.
Fluidigm initially invented this architecture to support a progressive new programme driven by the Agricultural Research Service (ARS), the chief scientific research agency of the United States Department of Agriculture (USDA). The programme's goal is to drive high sample throughput genotyping down to a penny-per-data-point, which would enable widespread adoption of genetic analysis in vegetable and fruit seeds, livestock (cattle, pigs, sheep, poultry) and fishery management. This will significantly improve the quality and quantity of the food supply, while lowering production costs.
“The ongoing challenge has been that genotyping simply costs too much to run the large number of experiments required to find the genetic markers that matter. Then, once found, the cost is still too prohibitive to implement these genetic quality controls across the millions and millions of seeds, animals and fish that make up our food production system," explained Curt Van Tassell PhD, ARS Research Geneticist.
“To achieve a tipping point necessary to transform industry and scientists, we needed to decrease the cost- per-data-point down to a penny - all in (chemical reagents, consumables)," added Van Tassell. "If we could achieve that type of cost structure, it would allow us to determine parentage and traceability information for under a dollar per animal. This low price point would allow animal evaluations under conditions that were not feasible before - such as in sub-Saharan Africa. This technology could provide the information to improve animals for some of the world's poorest livestock producers. By developing and using breed or trait specific panels, we can realise substantial gains in productivity across cattle as well as other livestock and plant species."
Circle no. 153 Circle no. 152 Circle no. 154
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
